news_6

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in ?-thalassemia Accepted for Review by China National Medical Products Administration

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China...